The Library
Clinically relevant drug interactions between anticancer drugs and psychotropic agents
Tools
Yap, Kevin Yi-Lwern, Tay, W.L., Chui, Wai Keung and Chan, Alexandre (2011) Clinically relevant drug interactions between anticancer drugs and psychotropic agents. European Journal of Cancer Care, Vol.20 (No.1). pp. 6-32. doi:10.1111/j.1365-2354.2009.01113.x ISSN 0961-5423.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1111/j.1365-2354.2009.01113.x
Abstract
Drug interactions are commonly seen in the treatment of cancer patients. Psychotropics are often indicated for these patients since they may also suffer from pre-existing psychological disorders or experience insomnia and anxiety associated with cancer therapy. Thus, the risk of anticancer drug (ACD)-psychotropic drug–drug interactions (DDIs) is high. Drug interactions were compiled from the British National Formulary (53rd edn), Lexi-Comp's Drug Information Handbook (15th edn), Micromedex® (v5.1), Hansten & Horn's Drug Interactions (2000) and Drug Interaction Facts (2008 edn). Product information of the individual drugs, as well as documented literature on ACD-psychotropic interactions from PubMed and other databases was also incorporated. This paper identifies clinically important ACD-psychotropic DDIs that are frequently observed. Pharmacokinetic DDIs were observed for tyrosine kinase inhibitors, corticosteroids and antimicrotubule agents due to their inhibitory or inductive effects on cytochrome P450 isoenzymes. Pharmacodynamic DDIs were identified for thalidomide with central nervous system depressants, procarbazine with antidepressants, myelosuppressive ACDs with clozapine and anthracyclines with QT-prolonging psychotropics. Clinicians should be vigilant when psychotropics are prescribed concurrently with ACDs. Close monitoring of plasma drug levels should be carried out to avoid toxicity in the patient, as well as to ensure adequate chemotherapeutic and psychotropic coverage.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
||||
Divisions: | Faculty of Science, Engineering and Medicine > Engineering > WMG (Formerly the Warwick Manufacturing Group) | ||||
Journal or Publication Title: | European Journal of Cancer Care | ||||
Publisher: | Wiley-Blackwell Publishing Ltd. | ||||
ISSN: | 0961-5423 | ||||
Official Date: | January 2011 | ||||
Dates: |
|
||||
Volume: | Vol.20 | ||||
Number: | No.1 | ||||
Number of Pages: | 27 | ||||
Page Range: | pp. 6-32 | ||||
DOI: | 10.1111/j.1365-2354.2009.01113.x | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access | ||||
Funder: | National University of Singapore |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |